Electrophysiology (EP) is a subspecialty of cardiology that focuses on diagnosing and treating heart rhythm problems. The electrical activity in the heart is measure, record, and treat with EP devices. These devices are use to diagnose & treat arrhythmias or irregular heartbeats. 

In 2021, the market for electrophysiology devices was worth USD 6.2 billion. And by 2030 it will reach USD 15.60 billion at a 10.8% CAGR during the forecast period. 

The rising rate of cardiovascular diseases. And the growing demand for minimally invasive procedures are the primary drivers of the electrophysiology devices market. Furthermore, the growing aging population and increased awareness about the early diagnosis and treatment of cardiovascular diseases drive market growth. However, the high cost of EP procedures and devices. And a scarcity of skilled EP specialists are major factors limiting the market growth.

Market Dynamics


Some key market growth drivers are the expanding use of electrophysiology devices in diagnosing. And treating cardiovascular diseases, including atrial fibrillation, the rising demand for cardiac rhythm management devices used for continuous monitoring. And the expanding use of these devices outside of hospitals. Another important reason driving the market’s expansion is the rising incidence of cardiac arrest. And heart failure (HF) cases among millennials as a result of lifestyle choices, including excessive alcohol intake and smoking.


The main factors hampering market growth are the availability of alternative medicines. The high costs connected with these goods, and the existence of tight regulations on electrophysiological devices.


Vendors of electrophysiology are anticipate to experience significant growth prospects in emerging regions. This is because there are more patients, more people with disposable cash, better healthcare infrastructure. And more lax regulations than in industrialized nations. Due to an expanding target patient population, an increase in CVD-related fatalities. And increased medical tourism, emerging countries have seen a consistent rise in surgical procedures over the past ten years.

Market Segmentation

By Application

In 2022, the diagnostic devices segment was responsible for more than 52.1% of the global revenue share. It is due to the high adoption rates of ambulatory monitoring equipment. And the widespread use of cardiac monitors as a standard diagnostic and monitoring tool for arrhythmias. Holter monitors, ECGs, diagnostic catheters, mapping & imaging systems, and implantable cardiac monitors are a few examples of EP diagnostic tools. Over the forecast period, segment growth will be fuel by the expanding usage of these devices in interventional medical procedures. Such as catheter placement, and the development of portable & digital systems.

By Indication

In 2022, the atrial fibrillation segment ruled the market with a revenue share of more than 32.3%. It is the most common type of arrhythmia. And it is link to an increase risk of stroke and blood clotting. Per the British Heart Association, approximately 1.5 million people in the United Kingdom will have atrial fibrillation by 2022.

By End-Use

In 2022, the hospital segment was the largest market, with 54.1% of the revenue share. The segment is dominate by interventional cardiologists’ adoption of technologically advance cardiac rhythm management. And EP systems, as well as the rising burden of Cardiovascular Disease (CVD). According to a study published in April 2018, daily short-term rhythm strip recordings revealed. A 13.0% increase in the elderly population hospitalized for atrial fibrillation, for a total prevalence of 46.0% in hospitalized patients.

Regional Overview 

North America was the market leader in 2021, with a revenue share of nearly 37.5%. Due to high rates of heart failure, cardiac arrest, and cardiac arrhythmia. During the forecast period, the presence of sophisticated healthcare infrastructure and favorable reimbursement policies will drive the region’s growth.

Throughout the projected period, the market in Asia Pacific will develop at the fastest rate. The high elderly population, rising risk of cardiac illnesses, and unmet clinical needs mostly drive the region’s expansion. Additionally, the region’s expanding healthcare spending rates, better patient awareness levels. And improved healthcare infrastructure will help manufacturers take advantage of these prospects.

Key Players 

  • Biotronik SE & Co. KG
  • Abbott Laboratories
  • Boston Scientific Corporation
  • GE electrophysiology (Healthcare)
  • CardioFocus, Inc.
  • Koninklijke Philips N.V.
  • Johnson & Johnson, Inc.
  • Siemens Healthineers AG
  • Stereotaxis, Inc.
  • AtriCure, Inc.
  • Medtronic Plc.
  • MicroPort Scientific Corporation
  • AngioDynamics
  • Biosense Webster

In 2021, the market for electrophysiology devices was worth USD 6.2 billion. And by 2030 it will reach USD 15.60 billion at a 10.8% CAGR during the forecast period. The growth of electrophysiology devices is due to the rising rate of cardiovascular diseases like heart failure, cardiac arrest, bradycardia, and atrial fibrillation. The market’s growth is also significantly influence by the rising demand for electrophysiology devices for continuous management. And monitoring of heart rhythm and the expanding uses of such devices in the hospital environment.

Related Reports:

Minimally Invasive Surgical Instruments Market Report – The global minimally invasive surgical instruments market will witness a robust CAGR of 7.21%, valued at $22.38 billion in 2021. Expected to appreciate and reach $43.76 billion by 2030, confirms Strategic Market Research.

Leave a Reply

Your email address will not be published. Required fields are marked *